ClinicalTrials.gg
CompletedNCT01289756Updated Feb 24, 2015

Influence of Pharmacogenetic Factors, Paroxetine and Clarithromycin on Pharmacokinetics of Clomiphene

A Phase 1 interventional study of Clomiphene and clomiphene and paroxetine in Anovulation, Disorder Due Cytochrome P450 CYP2D6 Variant and Cytochrome P450 CYP3A Enzyme Deficiency, sponsored by Robert Bosch Gesellschaft für Medizinische Forschung mbH. Completed at 1 site in Germany. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-02-24.

Sponsored by Robert Bosch Gesellschaft für Medizinische Forschung mbH · Phase 1, Interventional, and Basic science

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Study summary

Aim of the study is the clinical validation of the metabolism and the pharmakokinetic of Clomifen in correlation to CYP2D6 and inhibition of CYP3A4.

02

Conditions studied

  • Anovulation
  • Disorder Due Cytochrome P450 CYP2D6 Variant
  • Cytochrome P450 CYP3A Enzyme Deficiency

Browse trials for

Keywords

  • pharmacokinetic
  • clomiphene
  • CYP2D6 polymorphisms
  • inhibition of CYP2D6 and CYP3A4
03

In context

Anovulation

75 studies on the registry are indexed under Anovulation; 7 are open to participants now.

This study's enrollment of 20 is below the median of 80 across 52 interventional studies indexed under Anovulation.

Browse Anovulation studies →

Lead sponsor

Robert Bosch Gesellschaft für Medizinische Forschung mbH is the lead sponsor of 7 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy
  • Female caucasians
  • Age 18 - 45 years old
  • 18.5 - 26 kg/m2

Exclusion criteria

Exclusion Criteria:

  • Persons with known sensitivity of Clomifen and/or Paroxetine and/or Clarithromycin
  • Pregnancy/lactation period
  • Meno-/
  • Smokers
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    CYP2D6 EM

    clomiphene, clomiphene and paroxetine, clomiphene and clarithromycin

    Drug: Clomiphene · Drug: clomiphene and paroxetine · Drug: clomiphene and clarithromycin

  • Experimental
    CYP2D6 IM

    clomiphene, clomiphene and paroxetine, clomiphene and clarithromycin

    Drug: Clomiphene · Drug: clomiphene and paroxetine · Drug: clomiphene and clarithromycin

  • Experimental
    CYP2D6 PM

    clomiphene, clomiphene and paroxetine, clomiphene and clarithromycin

    Drug: Clomiphene · Drug: clomiphene and paroxetine · Drug: clomiphene and clarithromycin

  • Experimental
    CYP2D6 UM

    clomiphene, clomiphene and paroxetine, clomiphene and clarithromycin

    Drug: Clomiphene · Drug: clomiphene and paroxetine · Drug: clomiphene and clarithromycin

Interventions

06

What researchers measure

Primary outcomes

  1. Area under the plasma concentration versus time curve (AUC)of clomiphene

    AUC of clomiphene and metabolites

    Time frame: 1, 2, 4, 6, 8, 10, 12, 24, 72 and 168 hours after durg application

  2. Peak Plasma Concentration (Cmax)of Clomiphene

    Cmax of Clomiphene and metabolites

    Time frame: 1, 2, 4, 6, 8, 10, 12, 24, 72 and 168 hours after drug application

Secondary outcomes

  1. Clearance of Clomiphene

    Clearance of Clomiphene and metabolites

    Time frame: 4, 8, 12 and 24 hours after drug application

  2. Metabolomic

    Metabolomic

    Time frame: 4, 8, 12 and 24 hours after drug application

  3. Tmax of clomiphene

    Tmax of clomiphene and metabolites

    Time frame: 4, 8, 12, 24 hours after drug application

  4. Pharmacogenomics

    Pharmacogenomics

    Time frame: once

07

Study locations

1 site
  • Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology and University of Tuebingen
    Stuttgart, BW 70376, Germany
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2009, a primary completion of Nov 2014 and a completion of Nov 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2011
First posted
Feb 4, 2011
Start
Dec 2009
Primary completionActual
Nov 2014
CompletionActual
Nov 2014
Last update
Feb 24, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01289756
Lead sponsor
Robert Bosch Gesellschaft für Medizinische Forschung mbH
Responsible party
Matthias Schwab (Prof. M.D., Robert Bosch Gesellschaft für Medizinische Forschung mbH) — Principal investigator
First posted
Feb 4, 2011
Start date
Dec 2009
Primary completion
Nov 2014
Completion
Nov 2014
Last update
Feb 24, 2015

Study contacts

Matthias Schwab, Prof.
principal investigator · Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Clomiphene

Start the discussion